The two struck a deal Monday for Hims to offer official versions of Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy.

Hims and Hers (NYSE:HIMS) shares rose 10% Tuesday, adding to Monday’s 49% gain following analyst upgrades after the company announced a collaboration with Novo ...

Citi stays 'neutral' on Novo Nordisk as crowded obesity market threatens to erode its competitive edge Novo Nordisk (NYSE:NVO), the Danish pharma giant behind the Ozempic and Wegovy weight-loss drugs, ...

Danish pharmaceutical leader Novo Nordisk has transformed a legal confrontation with the telemedicine provider Hims & Hers into a collaborative venture. The ...

Novo Nordisk has signed an agreement with Hims & Hers Health that will allow the telehealth provider to offer FDA‑approved versions of Ozempic and Wegovy at self‑pay prices comparable to other digital ...

BLKBRD Asset Management exited 318,666 shares of Hims & Hers Health; estimated trade size $18.07 million, based on quarterly average pricing. Quarter-end position value dropped by $18.07 million, ...

After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 ...

Hims & Hers Health Inc HIMS shares are rising higher on Tuesday. Multiple analysts upgraded the stock following the company’s deal with Novo Nordisk this week. Hims & Hers has struck a new agreement ...

Hims & Hers Health has sparred with Novo Nordisk for months over the Danish drugmaker’s refusal to sell weight-loss drugs on its platform, but the bitter feud appears to have reached its end.

Needham analyst Ryan MacDonald upgraded Hims & Hers (HIMS) to Buy from Hold with a $30 price target after the announcement that Novo Nordisk (NVO) has set aside its differences and will partner with ...

Hims & Hers Health (NYSE:HIMS) shares climbed about 10% on Tuesday, extending Monday’s sharp rally of nearly 49% after analysts upgraded the stock following the company’s newly announced partnership ...

Amid the company’s efforts to resolve issues raised during an FDA inspection early last year, Novo Nordisk’s operating base in Plainsboro, New Jersey—already the recipient of a recent Form 483—has ...